Navigation Links
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Date:11/26/2013

tion correlates with the Mayo endoscopic score for disease severity. IL-6 levels were also significantly reduced (p=0.046) in patients treated with BL-7040, and most patients with reduced cytokine levels showed clinical improvement. 

"These positive results are an extension of the initial positive results of the Phase 2a trial for BL-7040, which showed that this promising drug is both safe and effective in treating ulcerative colitis. In fact, the clinical improvement in this trial was achieved after a relatively short treatment period, which leads us to believe that BL-7040 would have an even stronger beneficial effect after longer treatment duration," said Dr. Kinneret Savitsky, CEO of BioLineRx. "The new results, which show that BL-7040 significantly reduces inflammatory factors, such as neutrophils and cytokines, support BL-7040's mechanism of action – the ability to suppress the specific processes underlying the disease. Crohn's disease and ulcerative colitis, both forms of IBD, are prevalent conditions that affect the quality of life of millions of people across the globe. It is estimated that as many as 1.4 million persons in the United States suffer from these diseases. In addition to discomfort, which can be quite extreme, IBD can cause significant complications, including anemia, abscesses and more. Current treatments are far from satisfactory, and many people stand to benefit from a new and effective treatment for this condition. We believe that the positive results seen throughout the phase 2a study, as well its oral availability, make BL-7040 an attractive potential future treatment option."

About the Phase 2a Study                       
The Phase 2a trial was an open-label, proof-of-concept study to evaluate the efficacy, pharmacodynamics, safety and to
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
2. BioLineRx Reports Third Quarter 2013 Financial Results
3. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
4. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
7. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
10. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
11. BioLineRx to Present at 15th International Celiac Disease Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... of new cancer therapies, today announced its financial results ... provided an overview of recent Company highlights and expected ... host a business update conference call and live webcast ...
(Date:9/3/2015)... 3, 2015 Report Details ... that Market, its R&D and Sales Potentials ... of cancer-treating medicines? Visiongain,s new report gives you revenue predictions ... you discover financial data, R&D trends, opportunities, interviews and revenue ... analysis you see forecasted sales to 2025 at overall world ...
(Date:9/3/2015)... About cardiovascular implants ... or blockage of blood vessels. Cardiac disease is ... cholesterol, and high blood pressure. Coronary artery disease, ... failure are some of the major cardiac diseases. ... coronary arteries, is one of the most common ...
Breaking Medicine Technology:DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7Global Cardiovascular Implants Market 2015-2019 2
(Date:9/4/2015)... ... September 04, 2015 , ... A Union County charitable ... Core Compassion Project is a non-profit organization dedicated to offering Pilates scholarships to ... cancer treatments and recover their mobility, strength, and range of motion following breast ...
(Date:9/4/2015)... ... September 04, 2015 , ... San Francisco cosmetic dentist ... CEREC is a newer method for creating restorations through innovative imaging equipment and ... the need for multiple appointments, CEREC produces restorations with total precision for a ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way ... , The patent-pending K Med Cups provide a quick and simple way to brew a ... cold, flu or cough. As a result, they enhance comfort and health. The invention features ...
(Date:9/4/2015)... ME (PRWEB) , ... September 04, 2015 , ... ... focus on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at ... , Speakers at the 2015 symposium are doctors and researchers at the top ...
(Date:9/4/2015)... ... 04, 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in the ... the men’s 400 meters final, with an impressive 44.89 seconds at the 2015 North ... Costa Rica in August 2015. The 44.64 time is a new NACAC Championship record. ...
Breaking Medicine News(10 mins):Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3
... in human sexual desire can be attributed to genes, ... disorders in future//. ,Researchers led by Richard P. ... of Jerusalem, examined the DNA of 148 healthy male ... ,When they compared the results, they found ...
... of pandemonium with protesting students on the one side ... other, causing apparent commotion amongst patients. The groups, under ... protests. ,Patients have expressed consolation at the opening ... said “Normally, I have to wait for hours before ...
... to the study conducted by an international team of ... in southern Cameroon. The researchers analyzed the feces sample ... Africa. They collected 599 fecal samples from 10 forest ... affects the chimpanzees had a close resemblance to HIV-1, ...
... ADHD responded positively when treated with stimulant medications ... have proved that stimulant medications, such as mixed ... effective when compared with nonstimulant medications such as ... meta-analysis of 29 controlled-treatment studies representing the past ...
... doctors in three medical colleges in Delhi went ... in their anti-quota protests but compounding// the sufferings ... in Maulana Azad Medical College (MAMC), University College ... on daylong leave to express their resentment against ...
... is highly conducive for the cognitive development of the ... Infact, even moderated alcohol intake during the initial months ... ,The study conducted by the University of Pittsburgh School ... that those children, whose mothers had indulged in at ...
Cached Medicine News:Health News:Stimulant Medications More Effective In Treating ADHD Than Nonstimulants 2Health News:Mass Leave By Doctors Leaves Patients Helpless 2
... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
Rapid Exchange Stent Delivery System with Hepacoat...
Curved Tip, 23 Gauge Inner Cannula, Nylon Connector (Also available wtih straight tip) Overall length 60mm; Stainless steel...
Medicine Products: